An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.
Brendan Mcdermid | Reuters
Eli Lilly‘s weight-loss drug Zepbound confirmed promise as a treatment for sleep apnea — giving traders more self belief to preserve proudly owning the sphere’s most treasured smartly being-care firm even after it is been crushing the S&P 500’s efficiency over the past three years.